KEYNOTE-564: Pembrolizumab as Adjuvant Therapy

Opinion
Video

Medical experts examine how overall survival data from KEYNOTE-564 has influenced the use of pembrolizumab as adjuvant therapy.

Video content above is prompted by the following:

How has overall survival data from KEYNOTE-564 impacted the use of pembrolizumab as adjuvant therapy?

Recent Videos
5 experts in this video
5 experts in this video
Related Content
Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

ONCOLOGY Staff
November 5th 2022
Article

A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.

Recap: Recent Research in Multiple Myeloma

Recap: Recent Research in Multiple Myeloma

ONCOLOGY Staff
November 4th 2022
Article

At an Around the Practice program in Charlotte, NC, experts spoke about the most recent research in multiple myeloma.

Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

ONCOLOGY Staff
September 18th 2022
Article

Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.

Recap: Mayo Experts Review Treatment Options for Newly Diagnosed Multiple Myeloma

Recap: Mayo Experts Review Treatment Options for Newly Diagnosed Multiple Myeloma

ONCOLOGY Staff
July 17th 2022
Article

Expert panelists review key data from recent meetings on the management of multiple myeloma and consider how these can be applied to clinical practice.

Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

ONCOLOGY Staff
July 16th 2022
Article

Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.

Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma

Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma

ONCOLOGY Staff
June 20th 2022
Article

A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.